• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Anthracycline glycosides, which in form of pharmaceun- cal compositions, exhibit antitumoral activity. The anthracycline glycosides are of the general formula I in which R represents a hydrogen atom or a hydroxy group, one of R1 and R2 represents a methyl group, and the other of R1 and R2 represents a hydroxy group, and their pharmaceutically acceptable acid addition salts, a process for producing said compounds and pharmaceutical compositions containing same.
    公开号:SU993822A3
    申请号:SU802969264
    申请日:1980-08-29
    公开日:1983-01-30
    发明作者:Барджотти Альберто；Казинелли Джузеппе；Пенко Серджо；Аркамоне Федерико；Ди Марко Аурелио
    申请人:Карло Эрба С.П.А (Фирма)；
    IPC主号:
    专利说明:

    (B) METHOD FOR PREPARING ANTHRACYCLINE GLYCOSIDES
    This invention relates to a process for the preparation of new glycosidic derivatives with valuable pharmacological properties.
    The purpose of the invention is to obtain new useful compounds that expand the arsenal of means of influencing a living organism, possessing improved
    Oh he
    where R is H or OH;
    one of R-} and R2 is methyl; and the other he
    The conclusion is that solvent properties, compared with the closest structural analogues, are achieved by synthesizing the latter, based on the known glycosylation reaction of daunomycin.
    The goal is achieved according to the anthracycline glycoside method of the general formula
    (one)
    In dry methylene chloride, daunomycinone is condensed in the presence of an equimolar amount of silver trifluoromethanesulfonic acid and molecular sieve as a dehydrating agent at room temperature with 2,3,6-trideoxy-α-C-methyl-y-0-p-nitrobenzoyl -3 trifluoroacetamido-1-lyxohexopyranosyl chloride or 2,3 | 6-trideoxy-4-C-methyl-0-P-nitrobenzyl-i-arabinohexopyranosyl chloride to give the corresponding protected glycoside derivatives, all the protecting groups are removed with a soft alkaline hydrolysis and Highlight dissolved target R-4H, R-, CHj, RgsOH RsRo- R-jsCH,,,
    Compounds I-A, IB, IC and IB are useful as antitumor agents.
    The novel compounds were tested on Hela cells in vitro (exposure time 2k hours) and on P-388 ascites leukemia in mice compared with daunorubicin (daunomycin) and doxorubicin (adriamycin).
    Results ; The effects of compounds on HeEa cells that cause cloning are presented in Table. one.
    Table 1
    Continued table. I
    :::: i ::: i ::
    V-epi-C-Methyldaunorubicin HSE (1-C)
    Doxorubicin hydrochloride
    C-C-Methyldoxorubicin
    her (i-b).
    C-epi-C-Methyldoxy-rubic (1-D). -C-Methyldiuorubicin IA A-C-Methyldoxorubicin IB A-epi-C-Methyldaunorubicin IC C k -EPI-4-C-Methyldoxorubicin I-O 24 product, where R H using treatment with methanolic chloride in the form of hydrochloride, which is optionally reacted with a solution of bromine in chloroform, and the resulting 14-bromo-derivative is hydrolyzed with an aqueous solution of sodium formate at room temperature, followed by isolation of the target product where R is OH, in the form of hydrochloride Anthracycline glycosides of formula (I) have the following names:
    HeEa cells were exposed to drugs for 2A h, then sown on Petri dishes. The number of colonies was counted after five days.
    The activity of the compounds against ascitic leukemia P-388 in mice is presented in table. 2
    Table 2
    Mice were treated intraparenterally one day after inoculation of tumor cells.
     The average survival time of the treated mice in relation to the average survival time of the control mice, expressed as a percentage.
      Evaluated on the basis of macroscopic findings at autopsy.
    The duration of the survival time is maximum. All new compounds in a tolerant dose of p-388 leukemia showed comparable or higher activity than the activity of known compounds. Example 1. MTO-ParanItrobenzoyl-2, 3, b-tri-deoxy-β-methyl-3-trifluoroacetamido-1-lixo-hexopyranosyl chloride (II-A) is the original compound. A solution of 1 g (3.7 mmol) methyl-2, 3 6-tridesyksi-4-C-methyl-3-trifluoroacetamido-о-1-lixo-hexopyranose and (IV-A) in 20 ml of acetic acid and In ml of water are reacted for 2 hours. The solution is evaporated and 2,3,6-trideoxy-C-methi-1-3-trifluoroacetamido-ct-1-lixo-hexopyranose (VA) is obtained as a white solid with yield 0, 95 g (95% L melting point 181-182 e. (O1) | 3 "-127 (p. 1.a in methanol). The PMR spectrum (DMSO - db) showed absorption at t, 05 (s, CHa- Ci); 1.16 (d, CH3-C-5) and 5.27 (C-1-H). A solution of 0.75 g (2.9 mmol} of compound VA mixed with 10 ml of triethyl. Continuation of table 2 of amine and 20 ml of dry methylene chloride are treated with stirring, 2.200 g of p-nitrobenzoyl chloride and 0.220 g of t-dimethylaminopyridine are then heated for 90 minutes. The solution is evaporated and the residue is dissolved in 100 ml of chloroform, washed with 101% sodium bicarbonate solution and then treated with water, then over sodium sulfate. The residue obtained is chromatographed on a column of silica gel upon evaporation. Elution with a mixture of chloroform and acetone in the ratio of 95: 5 gives 1- -di-0-p-nitrobenzoyl-2,3, -tridezoxy-C-methyl-3-trifluoroacetamido-L-lix-hexopyranose (Vi-A, 1, 55 g, 95%) melting point 168-170, (ot) 2, ° -35 ° C (s 1.0 in chloroform). A solution of 1.10 g (2.0 mmol) of compound VI-A in 25 ml of dry methylene dichloride is saturated at 0 ° C with anhydrous hydrogen chloride. The resulting p-nitrobenzoic acid precipitate is filtered under anhydrous conditions and the filtrate is evaporated. 2,3, b-trideoxy-C-methyl-0-N-nitrobenzoyl-3-triftoperacetamido-L-lixo-hexopyranosyl 7 chloride (11-A, 0.80 g) is obtained as a white solid, suitable for further synthesis without additional purification. Example 2. L-0-P-Nitrobenzoyl-2, 3,6-tridesoxy-C-methyl-3-trifluoroacetamido-L-arabino-hexopyranosyl chloride (M-B) is the starting compound .; Acid hydrolysis of methyl-2,3,6-tridesoxy-C-methyl-3 trifluoroacetamido-cC-L-arabino-hexopyranoside (IV-B, 0.80 g, 3 mmol) as in Example 1 gives 2,3,6 -tridezoxy-C-methyl-3 trifluoroacetamido-b (g1-arabino-hexopyranose (VB, 0.700 90%) as a solid with a melting point of 110-111 s, (ot) | 5 "-83 (with 1, 0 in methanol). PMR spectrum (CDS + DMSO-44) shows absorption at: 1.10 (s, CH3-Ci), 1.17 (d-) and 5.23 (broad singlet, CIH), Processing Compound VB (0.60 g 2.33 mmol) of para-nit1-eo-benzoyl chloro with 1 as in Example 1 gives the corresponding derivative 1, -di-O-para-nitrobenzoyl (VI-B, 1.030 g, 80 g with melting point.) .a nn; "1 C 1 P Iff 1 JE -21 ° (c 1.1 in chloroform). A solution of 0.90 g (1.62 mmol) of Vf-Bs 20 ml of dry dichloride methylene is saturated with anhydrous hydrogen chloride.After filtering the precipitate with p-nitrobenzoic acid, the solution is evaporated to dryness to obtain 2,3,6-trideoxy-C-methyl-0-p-nitrobenzoyl-3-trifluoroacetamido-L-arabino-hexopyranosyl chloride (pb, 0.650 g) in the form of a white solid suitable for further use without further purification. Example 3.-C-methyl-dauno rubicin (1-A) (IMI-105). To a solution of daunomycin (0.900 g, 2.26 mmol) in dry megylene chloride (90 ml) was added 2, J, 6; -tridezoxy-4-C-methyl-0-p-nitrobeisoyl-3-trifluoroacetamido-1- lyxohexrpyranosyl chloride (| 1-A) (0.800 g) prepared as in Example 1, in 15 ml of methylene dichloride and in the presence of molecular whitefish (Merck, iA, 6 g). The mixture is then treated with 0.58 g of the silver salt of three fluoromethanesulfonic acid in anhydrous diethyl ether (15 ml) with vigorous stirring. 2 After one hour at room temperature, the reaction mixture is neutralized with a saturated aqueous solution of sodium bicarbonate, the organic phase is separated and evaporated in vacuo. Chromatographic purification of the crude residue on a silica gel column using a mixture of chloroform and acetone in the ratio as the mobile phase yields 0.9b5 g (b5) -C-methyl-0-p-nitrobenzoyl-N-trifluoroacetyldaunorubicin with a melting point of 172-173 ° C . W (from 0.05 in chloroform). - The NMR spectrum (SDS) shows absorption at 1.28 (d, CHj-C-5); 1.56 (s, CH3-C-A); 2.8 (s, SNSO); 4.02 (s, OCHj); 5.21 (broad singlet, C-7-H); 5.50 (broad singlet, CI-H); 13, Pi 13.92 (two singlet, phenol group OH). A solution of 0.8 g of the compound obtained above in 15 ml of acetone is treated with ml of 0.1N. a solution of aqueous sodium hydroxide and stirred at room temperature under a nitrogen atmosphere. After one hour, the pH of the reaction mixture is 1 n. aqueous hydrogen chloride is adjusted to 3.5 and then extracted with chloroform to separate impurities. The pH of the aqueous phase is adjusted to 8.0 and extracted twice with chloroform. The combined organic extracts are dried with sodium sulfate, concentrated to a small volume, and acidified to pH = 5 0.25 n. hydrogen chloride in methanol. The addition of an excess of diethyl ether gives -C-1methyl-daunorubicin (I-A) in the form of hydrochloride (0.515 g, 88%) with a melting point of 1b2-1b3S (with decomposition). (i) g 320 ° (c 0.05 in methanol). PRI me R. 4-C-methyl-doxorubicin (1-B) (M1-109). A solution of 4-C-methyl daunorubicin hydrochloric acid (1-A, 0, "5-0.78 mmol), prepared as in Example 3, mixed with 6 ml of anhydrous methanol, 17.5 ml of dioxane and O, ml of ethyl ether Orthoformic acid is treated with 1.8 ml of a solution containing 0.95 g of bromine in 10 ml of chloroform. After 1.5 h, with the reaction mixture, it is poured into a mixture of 90 ml of di-ethanol and 45 ml of lethroleic ether. The resulting precipitate is red after filtration and washing with diethyl
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining glycosides of anthra of the general formula o on cyclin
    ССНгК 'ОН н / о н э е. Κι
    Kt where R is one of OH, so that daunomycin, dissolved in dry methylene chloride, is condensed in the presence of an equimolar amount of a silver salt of trifluoromethanesulfonic acid and a molecular sieve · as a dehydrating agent at room temperature with 2,3,6-trideoxy-4-C- methyl 4-0-p-nitro ; Benzoyl-3 ~ trifluoroacetamido-L-dioxohexo-pyranosyl chloride or 2,3,6-trideoxy-4-C-meT'yl-4-0-p-nitrot benzoyl-L-arabinohexopyranosyl chloride with the preparation of the corresponding protected glycoside derivatives, all protective groups are removed by mild, alkaline hydrolysis and the desired product is isolated, where R Н, by treatment with methanolic hydrogen chloride in the form of hydrochloride, which, if necessary, is reacted with a solution of bromine in chloroform, and the resulting -14-bromo-aqueous is hydrolyzed with an aqueous solution formate nat tions at / room temperature followed by isolation of the desired product, where R - OH, as hydrochloride.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0041355A1|1981-12-09|Novel erythromycin compounds
    SU993822A3|1983-01-30|Process for producing antracycline glycosides
    SU897111A3|1982-01-07|Method of preparing anthracycline derivatives
    EP0051280B1|1984-07-11|Anthracycline glycosides, process for the preparation thereof, intermediate compounds and their preparation and pharmaceutical compositions
    US4188377A|1980-02-12|Carminomycin derivatives, their preparation and use
    US4684629A|1987-08-04|3'-deamino-3'-hydroxy-4'-deoxy-4'-amino doxorubicin and related daunorubicin
    US4393052A|1983-07-12|Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
    SU797583A3|1981-01-15|Method of preparing anthracycline-glycosides
    SU1017173A3|1983-05-07|Process for preparing anthracycline glycosides
    US4199571A|1980-04-22|Substituted anthracyclines, their preparation and use
    SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides
    AT392793B|1991-06-10|METHOD FOR PRODUCING NEW ANTHRACYCLINGLYCOSIDES
    CA1091225A|1980-12-09|Anthracyclines
    SU1553015A3|1990-03-23|Method of producing anthracyclinic glycosides
    RU2073681C1|1997-02-20|Anthracycline glycoside and method of its synthesis
    CS270411B2|1990-06-13|Method of new 4 halogen anthracycline glycosides production
    MX2007005543A|2008-03-04|Compositions and processes for preparing 13-deoxy-anthracyclines.
    SU902667A3|1982-01-30|Method of preparing desoxyanthracyclines
    CA1091657A|1980-12-16|New antitumor agent 9-deacetyl-9 ethylene oxyde daunorubicin hydrochloride
    SU963471A3|1982-09-30|Process for producing glicozides
    IE911634A1|1991-11-20|3'-deamino-4'-deoxy-4'-amino-8-fluoroanthracyclines and¹processes for their preparation
    US4604381A|1986-08-05|4-demethoxy-13-dihydrodaunorubicin and use thereof
    GB2034707A|1980-06-11|Anthracycline glycosides
    SU1277902A3|1986-12-15|Method of producing 4'-deoxy-daunorubicyn or 4'-deoxy-doxorubicyn
    CS158792A3|1992-12-16|Chemical modification of 3' and/or 4'-oh group elsamycin a
    同族专利:
    公开号 | 公开日
    CA1154013A|1983-09-20|
    AT1101T|1982-06-15|
    US4325946A|1982-04-20|
    EP0024727B1|1982-05-26|
    DE3060472D1|1982-07-15|
    IT8024348D0|1980-08-29|
    DK368580A|1981-03-02|
    EP0024727A1|1981-03-11|
    JPS6328077B2|1988-06-07|
    IT1201937B|1989-02-02|
    JPS5636498A|1981-04-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3803124A|1968-04-12|1974-04-09|Farmaceutici It Soc|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives|
    GB1467383A|1974-06-12|1977-03-16|Farmaceutici Italia|Daunomycin analogues|
    GB1506200A|1975-04-30|1978-04-05|Farmaceutici Italia|Glycosides|
    GB1511559A|1975-09-26|1978-05-24|Farmaceutici Italia|Anthracycline glycosides|
    US4133877A|1976-07-08|1979-01-09|Societa Farmaceutici Italia S.P.A.|Anthracycline ethers and use therefor|
    GB1573036A|1977-05-05|1980-08-13|Farmaceutici Italia|Anthracyclines|
    US4265885A|1978-10-25|1981-05-05|Farmitalia Carlo Erba S.P.A.|Anthracyclines containing branched-chain amino-deoxy sugars|AT15375T|1980-11-01|1985-09-15|Erba Farmitalia|ANTHRACYCLINE GLYCOSIDES, INTERMEDIATE PRODUCTS, METHOD FOR BOTH PRODUCTION AND MEDICINAL PRODUCTS.|
    AT378372B|1981-08-22|1985-07-25|Erba Farmitalia|METHOD FOR PRODUCING NEW ANTHRACYCLINES|
    GB8708927D0|1987-04-14|1987-05-20|Erba Farmitalia|Chiral synthesis of anthracyclines|
    DE3722698A1|1987-07-09|1989-01-19|Behringwerke Ag|CYTOSTATICALLY EFFECTIVE ANTHRACYCLINE DERIVATIVES|
    US4921847A|1988-05-23|1990-05-01|Engelhard Corporation|Trihalogold anti-tumor complexes|
    GB9216962D0|1992-08-11|1992-09-23|Erba Carlo Spa|Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives|
    DE59911077D1|1998-08-17|2004-12-23|Bayer Materialscience Ag|Aqueous coating agent, its production and use for stoving enamels|
    DE10047289A1|2000-09-25|2002-04-11|Bayer Ag|Low temperature drying aqueous coatings|
    KR20130027576A|2007-08-06|2013-03-15|사비팜 인크.|Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives|
    DK1990405T3|2007-05-08|2017-11-06|Provivo Oy|Genetically modified strains producing anthracycline metabolites useful as cancer drugs|
    US20110171691A1|2008-09-11|2011-07-14|W.C. Heraeus Gmbh|Genetically modified strains for biotransformations in anthracycline production|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7930392|1979-09-01|
    [返回顶部]